BryoLogyx

BryoLogyx is a drug research company that is developing a new type of drug to improve the response rate and treatment durability of cancer immunotherapy. BryoLogyx is leveraging two recent scientific advancements: the discovery that a complex natural product, bryostatin, can stimulate the production of tumor antigens, thereby amplifying the immune response unleashed by cancer immunotherapy; and the invention of the first practical synthetic production method for bryostatin and its analogs, making it commercially viable for development.